Regeneron Pharmaceuticals Inc. (REGN)

380.69
7.11 1.83
NASDAQ : Health Technology
Prev Close 387.80
Open 384.17
Day Low/High 377.09 / 387.19
52 Wk Low/High 281.89 / 437.90
Volume 773.87K
Avg Volume 678.10K
Exchange NASDAQ
Shares Outstanding 106.14M
Market Cap 42.12B
EPS 11.30
P/E Ratio 28.25
Div & Yield N.A. (N.A)

Latest News

FDA Approves Asthsma Indication For Dupixent® (dupilumab)

FDA Approves Asthsma Indication For Dupixent® (dupilumab)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

Kevzara® (sarilumab) Data At The 2018 ACR/ARHP Annual Meeting Provide Additional Insight On Safety And Efficacy In Rheumatoid Arthritis

Kevzara® (sarilumab) Data At The 2018 ACR/ARHP Annual Meeting Provide Additional Insight On Safety And Efficacy In Rheumatoid Arthritis

Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response

Dupixent® (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

Dupixent® (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery

Libtayo® (cemiplimab-rwlc) Data At ESMO 2018 Congress Provide New Insights In Six Tumor Types Under Investigation

Libtayo® (cemiplimab-rwlc) Data At ESMO 2018 Congress Provide New Insights In Six Tumor Types Under Investigation

- ESMO data demonstrate breadth of joint Regeneron and Sanofi immuno-oncology development program

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Fri. 8/31/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Fri. 8/31/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva And Regeneron Announce Positive Topline Phase 3 Fasinumab Results In Patients With Chronic Pain From Osteoarthritis Of The Knee Or Hip

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.

Regeneron Soars After My 'Go Long' Recommendation: What Now?

Regeneron Soars After My 'Go Long' Recommendation: What Now?

An updated strategy for the high-flying REGN.

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Thursday 7/26/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Thursday 7/26/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

TheStreet Quant Rating: B- (Buy)